Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1384&sort=-program_officials
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-program_officials", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1392&sort=-program_officials", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1385&sort=-program_officials", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1383&sort=-program_officials" }, "data": [ { "type": "Grant", "id": "10675", "attributes": { "award_id": "1U01IP001191-01", "title": "Evaluating influenza, SARS-CoV-2, and other respiratory virus vaccine effectiveness in prevention of acute illness in Washington state 2022-2027", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-30", "end_date": "2027-09-29", "award_amount": 2000000, "principal_investigator": { "id": 26733, "first_name": "Karen J", "last_name": "Wernli", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1955, "ror": "", "name": "KAISER FOUNDATION HEALTH PLAN OF WASHINGTON", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "As one of the current US Influenza Vaccine Effectiveness (US Flu VE) Network sites, we propose continuing our studies of vaccine effectiveness (VE) for seasonal influenza, COVID-19, and other respiratory viruses to prevent acute respiratory illness (ARI) in Washington state from 2022 to 2027 (Component A). Since March 2020, the COVID-19 pandemic has resulted in >80 million infections and ~1 million US deaths. Until the pandemic, the dominant respiratory virus impacting public health seasonally was influenza. In the US, up to 5% of the population sought outpatient care during a severe epidemic, and a typical epidemic caused tens of thousands of deaths and hundreds of thousands of hospitalizations. The COVID-19 pandemic catalyzed rapid adoption of telehealth care, in particular for patients with mild to moderate ARI, shifting patients from ambulatory visits to minimize healthcare exposure to COVID-19. Currently, influenza and COVID-19 vaccinations are the best available tools for reducing the respiratory virus burden and maintaining population immunity. Vaccination programs represent a substantial public health investment. Given the magnitude of this investment and the dynamic impact of respiratory viruses on public health, policymakers need accurate, timely, and relevant data representing real-world VE to monitor the impact on respiratory illness burden in US populations. The next 5 years of surveillance of respiratory illness in US populations will be critical in accounting for changes in respiratory virus burden. The US Flu VE Network has the capacity, infrastructure, research methods, and specimen collection experience to monitor any respiratory virus within US health care. From 2022-2027, we propose to enroll ~6000 KPWA infants, children, and adults including older adults in urgent care clinics, collect respiratory and blood specimens, complete enrollment and post-enrollment questionnaires, collaborate with laboratory services to type and genetically sequence specimens, collate and curate EHR data, collaborate across the Network with Component A sites, share data with Network Coordination Center (Component B), share specimens with site leading Component E, participate in Network research activities including dissemination, and develop new methods for estimation and inference in VE. Our specific aims to meet the goals of the US Flu VE Network are: Aim 1. Establish a platform to estimate VE of seasonal influenza and COVID-19 vaccines against respiratory viral illnesses in preventing laboratory- confirmed illness among children and adults with mild or moderate illness seeking care in ambulatory settings (Objective 1); Aim 2. Establish a protocol to obtain influenza and SARS-CoV-2 viral sequences from specimens collected among infected participants in the proposed outpatient network (Objective 2); Aim 3. Describe capacity and diagnostic test methods available in KPWA and methods to obtain COVID-19 vaccination data outside influenza season (Objective 3). Aim 4. Improve precision of the test-negative design by incorporate two-phase sampling methodology (methods aim).", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10677", "attributes": { "award_id": "1R43GH002392-01A1", "title": "Rapid Point-of-Care Molecular Test for SARS-CoV-2 and Influenza A/B", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-30", "end_date": "2023-03-31", "award_amount": 275766, "principal_investigator": { "id": 26734, "first_name": "SEASON S-S", "last_name": "WONG", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1734, "ror": "", "name": "AI BIOSCIENCES, INC.", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "The goal of this Phase I SBIR proposal is to develop a 15 minute multiplex point-of-care (POC) molecular test for the qualitative detection of COVID-19 and influenza A/B. As of September 2021, the US has had over 39.5 million confirmed cases of COVID-19 and over 642,000K deaths. Additionally, influenza viruses account for over 200,000 hospitalizations and 30,000–50,000 deaths in the US each year. As SARS-CoV-2 and influenza infections can hardly be differentiated by symptoms alone, a single test that can diagnose illness caused by SARS-CoV-2 and influenza viruses will give public health officials information they need in their efforts to control the spread of these important viruses of concern. Our approach leverages rapid sample preparation (1 min hands-on-time and 2.5 minute of heat inactivation) and the rapid gold-standard real-time RT-PCR (12 minute, 40-cycle) to amplify the targeted viral genome. This test can be utilized in multiple settings where actionable test results are needed to make informed treatment decisions quickly. We will demonstrate that our test can deliver rapid results with a similar level of performance as those obtained in reference labs using nasopharyngeal swabs and contrived saliva samples. Our approach has been tested using SARS-CoV-2 and influenza positive clinical specimens in viral transport media. We plan to achieve rapid multiplex RT-PCR using shuttle PCR with thin-film reactors. We can enhance PCR speed and efficiency by using vibration to enhance reagent mass-transport while avoiding the “extreme PCR” approach that needs 10 to 20 times more concentrated reagents (i.e., additional expense) to speed up the reaction. The result from spatial multiplexed fluorescence probe-based RT-PCR can be imaged and analyzed by on-board electronics. The RT-PCR test takes ~8 minutes to complete 40 cycles after 2.5 min of sample heat inactivation and 3 min of reverse-transcription step, and some high positive results can be obtained in as early as 6 minutes. Our approach will be much more sensitive than antigen-based approaches and faster than isothermal amplification approaches, such as loop mediated isothermal amplification (LAMP). The diagnostic utility of the molecular assay will be demonstrated by comparing its robustness, speed, sensitivity, and specificity with current molecular assays. In Phase I, we will work with our collaborator to validate our device and test using clinical specimens. If successfully developed, this compact and minimal instrumentation approach will be simple to perform and inexpensive enough for all sizes of primary-care physician’s offices, nursing homes, pharmacies, community health clinics, and even at-home consumers to adopt the platform.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10685", "attributes": { "award_id": "272201700040I-0-759302200006-1", "title": "Task C14: Advancing Human Lung Microphysiological Systems to Model Coronavirus Infection and Test Candidate Countermeasures", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-23", "end_date": "2024-03-22", "award_amount": 1108255, "principal_investigator": { "id": 26740, "first_name": "JENNIFER", "last_name": "YOUNG", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 851, "ror": "", "name": "UNIVERSITY OF TEXAS MED BR GALVESTON", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "This contract provides for the development and standardization of difficult-to-source reagents that require the use of nontraditional animal models of infectious diseases.", "keywords": [ "2019-nCoV", "Animal Model", "Basic Science", "COVID test", "Contracts", "Coronavirus Infections", "Development", "Human", "Lung", "Modeling", "Reagent", "Source", "Standardization", "infectious disease model", "microphysiology system" ], "approved": true } }, { "type": "Grant", "id": "10687", "attributes": { "award_id": "1R43GH002390-01A1", "title": "Pan-COVID Therapeutic", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-30", "end_date": "2023-03-29", "award_amount": 275766, "principal_investigator": { "id": 26741, "first_name": "JAMES W", "last_name": "LARRICK", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26742, "first_name": "Bo", "last_name": "Yu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1958, "ror": "", "name": "LARIX BIOSCIENCE, LLC", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Pan-COVID Therapeutic Abstract Severe COVID-19 remains as an urgent unmet clinical need for unvaccinated people, particularly as the SARS- CoV-2 delta and omicron variants spread globally. Despite the rapid deployment of effective vaccines, a large percentage of Americans are not fully vaccinated. About 15% of COVID-19 patients require hospitalization with 5% requiring intensive care, among whom nearly half of patients succumb to the disease without an effective therapeutic option. Because angiotensin-converting enzyme 2 (ACE2) is the cell surface receptor of the SARS- CoV-2 spike (S) glycoprotein for cell entry, soluble ACE2 has been used as a decoy receptor to inhibit SARS- CoV-2 infection in vitro and in vivo. However, the affinity of the wild type human ACE2 is not high enough (tens of nM) to warrant therapeutic development. We have generated a high affinity ACE2 (>100-fold). This engineered ACE2 will be effective against all variants, including delta. Fusion of this engineered ACE2 to a human immunoglobulin Fc region is expected to result in superior pharmacokinetics, as Fc will confer a long circulating half-life and the ability to be delivered to airway mucosal surfaces, the primary site of SARS-CoV-2 infection. Unlike anti-SARS-CoV-2 antibodies, the ACE2-Fc decoy fusion protein will not subject the virus to selection for neutralization escape mutants, as any mutation that decreases binding to the decoy will reduce binding to the native receptor, resulting in an attenuated virus. Our engineered ACE2 maintains the peptidase activity that decreases angiotensin II (Ang II) concentration to alleviate AGTR1/AGTR2-mediated vasoconstriction that exacerbates the acute respiratory distress. The active ACE2-Fc will address the underlining pathogenesis of severe COVID-19 in addition to blocking the viral entry, and provides superior efficacy versus neutralizing antibodies. During this Phase 1 project, we will engineer an active ACE2 with >100-fold affinity improvement to the SARS-CoV-2 spike protein, and fuse it to a human Fc. The resulting decoy fusion protein will inhibit viral binding to its receptor ACE2 as well as locally target the renin–angiotensin system (RAS) to attenuate severe respiratory distress. The outcome of this work will be a novel best-in-class therapy for SARS-CoV-2 and potentially other viral acute respiratory distress syndromes.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10688", "attributes": { "award_id": "75N95021D00029-0-759502200003-1", "title": "SECURE PLATFORMS SUPPORT FOR THE N3C DATA ENCLAVE (COVID-19)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)", "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-25", "end_date": "2022-12-17", "award_amount": 4225000, "principal_investigator": { "id": 26481, "first_name": "BRIAN", "last_name": "ZAVERTNIK", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1737, "ror": "", "name": "PALANTIR TECHNOLOGIES, INC.", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true }, "abstract": "National COVID-19 Cohort Collaborative (N3C): The National COVID-19 Cohort Collaborative (N3C) sponsors the NIH COVID-19 Data Enclave, https://covid.cd2h.org/, one of the largest data enclaves in the world supporting COVID-19 research. N3C is a partnership among the NCATS-supported Clinical and Translational Science Awards (CTSA) Program hubs, the National Center for Data to Health (CD2H), and the NIGMS-supported Institutional Development Award Networks for Clinical and Translational Research (IDeA-CTR), with overall stewardship by NCATS. The N3C Data Enclave is a secure platform storing harmonized clinical data provided by more than 60 contributing members. The Enclave hosts over 670 million clinical observations on over 6.8 million persons, including over 2.2 million COVID cases, amounting to more than 7.8 billion rows of data. To protect privacy, this data consists only of limited data sets, de-identified data sets, and synthetic data sets; there is no personally identifiable information kept in the Enclave. The Enclave resides in the NCATS Secure Scientific Platforms Environment. The Environment is a specialized cloud-based data aggregation and analytics enclave that can integrate, manage, secure, and analyze any kind of scientific data, and provide secure, controlled access to internal and external collaborators. Within the Environment, multiple NIH ICs, Federal agencies, and Federal task forces integrate, manage, secure, and analyze all types of scientific data using dedicated platforms, and, equally importantly, make that data available in specific and controlled collaborations with each other and with external collaborators.", "keywords": [ "Advisory Committees", "Award", "COVID-19", "Clinical", "Clinical Data", "Clinical Research", "Clinical and Translational Science Awards", "Collaborations", "Data", "Data Aggregation", "Data Analytics", "Data Set", "Development", "Environment", "Health", "National Center for Advancing Translational Sciences", "National Institute of General Medical Sciences", "Personally Identifiable Information", "Persons", "Privacy", "Research", "Secure", "Translational Research", "United States National Institutes of Health", "cloud based", "cohort", "coronavirus disease", "data de-identification", "data enclave", "member", "programs" ], "approved": true } }, { "type": "Grant", "id": "10692", "attributes": { "award_id": "1U01IP001184-01", "title": "RFA-IP-22-004, Evaluating respiratory virus vaccine effectiveness in a large, diverse healthcare system", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-30", "end_date": "2027-09-30", "award_amount": 2495017, "principal_investigator": { "id": 26748, "first_name": "RICHARD K", "last_name": "ZIMMERMAN", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 848, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "– Component A We are applying for RFA components A and D. This abstract refers to Component A. Influenza/pneumonia comprise the 9th and COVID-19 the 3rd leading cause of death in the U.S., with the pandemic entering its 3rd year. Vaccine effectiveness (VE) estimates vary by host factors, viral clade, match to circulating virus, time since vaccination (i.e., waning) and specific vaccine characteristics. PittVax and collaborators have been integral to the US Flu VE Network for 12 years, contributing to influ- enza and COVID-19 VE estimates. Among the current 7 Network sites, PittVax ranks #2 in enrollments, #2 in bloodspot collections, and #1 in follow-up survey completion, while exceeding enrollment goals. PittVax has published >300 peer-reviewed articles in the field. We propose a test-negative case-control design (TND) study among UPMC and federally qualified health center (FQHC) outpatients to determine influenza, COVID-19 and possibly, other respiratory virus VE. Our specific aims are: 1) Determine VE against laboratory-confirmed, medically-attended, acute respiratory in- fections among 1000-1200 outpatients during the influenza season in age groups: 6 mos-18 yrs, 19-49 yrs, and ≥50 yrs, using test negative design in onsite enrollment during respiratory season plus remote enroll- ment outside of influenza season (another 400-900 if COVID-19 persists); 2) provide genetic sequencing on selected specimens for biweekly trends in clade; and 3) determine the annual, population-based burden of influenza and COVID-19 for Allegheny County (Pittsburgh) from the UPMC Health Plan. For determining prior infection for SARS-CoV-2 (e.g., N protein) in the highest proportion of participants, we propose finger- stick bloodspots, supplemented by sera on a subset, for more in-depth studies. The Williams lab, using vali- dated 96-well plate instruments for RT-PCR, which analyzed >10,000 specimens over the last 6 years for influenza, SARS-CoV-2 and other respiratory viruses, will determine presence of infecting viruses. The ex- perienced Harrison lab will perform viral genomic sequencing. We will obtain immunization records from the state’s registry and from UPMC’s and the FQHC’s electronic records. UPMC Health Plan is the largest insurer in Allegheny County and at UPMC in 2021-22, >126,000 county residents were clinically tested for SARS-CoV-2. Annually, UPMC records >5.6 million outpatient visits. Over 1.4 million UPMC acute care visits a year are assessed at Emergency Departments (EDs) and Urgent Care clinics through a common structure and e-record with 305,751 ED visits in 2021 among our four recruiting EDs. UPMC has been rated one of the most wired health systems for 23 years. To address health equity, we add FQHC offices serving mostly persons of color and leadership from the Black Equity Coalition to our multidisciplinary team to assist with culturally competent script/survey development, inclusion of social deter- minants of health data and dissemination of findings with a health equity perspective.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10694", "attributes": { "award_id": "1IK2HX003427-01A2", "title": "Provision of high quality telemental health care during COVID-19 and beyond", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-10-01", "end_date": "2027-09-30", "award_amount": null, "principal_investigator": { "id": 26751, "first_name": "Samantha L", "last_name": "Connolly", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1521, "ror": "", "name": "VA BOSTON HEALTH CARE SYSTEM", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Background: Telemental health (TMH) via videoconferencing or phone can increase Veterans’ access to mental health (MH) care. TMH can eliminate barriers including travel distance and cost, as well as physical limitations, caregiving responsibilities, and MH symptoms that can make leaving home difficult. Prior to COVID- 19, rates of TMH in VA were low (~9%). There was a dramatic shift towards TMH during COVID-19 to prevent infection, with ~50% of care delivered by phone, ~25% by video, and ~25% in-person. Benefits and drawbacks of phone, video, and in-person care must be considered when choosing a MH care modality. If patients, providers, and/or leadership believe that phone care is equivalent in quality to video and/or in-person, they may be more likely to choose this modality as it often has the fewest barriers to use; however, based on limited evidence, phone care may be lower quality than video and in-person. We need more nuanced analyses regarding: 1) the relative quality of phone, video, and in-person care (e.g., for more complex patients, for psychotherapy sessions versus shorter medication management appointments), and 2) patient preferences. As a clinical psychologist and HSR&D investigator with TMH experience, I am well-positioned to conduct this research. This proposal will provide key methodological training and advance me toward my goal of becoming a leading health services researcher and implementation scientist with expertise in telehealth. Significance/Impact: MH, telehealth, access, and quality of care are all major HSR&D research priorities. The increased use of TMH during COVID-19 has led to a wealth of untapped data through which we can examine the relative quality of TMH care as well as patient preferences across modalities, in order to improve care modality decision-making processes. Results, which will incorporate data from millions of patients and thousands of providers, have the potential to impact delivery of high-quality MH care on a national scale. Innovation: To our knowledge, there has been no published research that: 1) compares the quality and patient preference of phone, video, and in-person MH care, and 2) uses this information to develop and implement evidenced-based strategies to increase video use when clinically effective and preferred by patients. Specific Aims: Aim 1: Examine quality outcomes of phone, video, and in-person MH care (e.g., differences in MH hospitalization rates). Hypothesis: Video care will be equivalent to in-person care and superior to phone care for more complex patients (e.g., history of MH hospitalization, 3+ MH diagnoses) and for psychotherapy appointments. Aim 2: Qualitative interviews with MH patients, providers, and leadership. Research question: What are facilitators/barriers to video use based on stakeholder attitudes, preferences, and decision-making processes, and how do these factors vary between sites with high levels of phone, video, and in-person care? Aim 3: Develop/pilot implementation strategies to increase video use in circumstances where it is clinically effective and preferred by patients. Hypothesis: Implementation strategies will increase video use. Methodology: In Aim 1, I will test for differences in quality outcomes between modalities via a sample of ~2 million Veterans who received MH care between 3/2020-3/2021 using comparative effectiveness research strategies. In Aim 2, I will conduct interviews with key stakeholders to understand facilitators and barriers to video use based on attitudes, preferences and current decision-making processes. In Aim 3, I will synthesize Aim 1 and 2 findings to develop and pilot implementation strategies at one VISN 1 MH site to increase video use in circumstances where it is clinically effective and preferred by patients. Strategies will be targeted at the patient, provider, and/or system levels based on Aim 1 and 2 findings. Next Steps/Implementation: The piloted strategies will be spread to additional MH sites, and ultimately other clinical services, via hybrid implementation-effectiveness trials in subsequent IIRs. Findings will be communicated to MH and Connected Care operational partners to inform the future of VA MH care delivery.", "keywords": [ "Academy", "Address", "Anxiety", "Appointment", "Attitude", "COVID-19", "COVID-19 pandemic", "Caring", "Clinic", "Clinical", "Clinical Services", "Collaborations", "Comparative Effectiveness Research", "Complex", "Data", "Decision Making", "Development", "Diagnosis", "Effectiveness", "Ensure", "Future", "Goals", "Health Services", "Health Services Accessibility", "Health Technology", "Healthcare", "Home", "Hospitalization", "Hybrids", "Infection", "Infection prevention", "Interview", "Leadership", "Medication Management", "Medicine", "Mental Health", "Mental Health Services", "Mentors", "Methodology", "Methods", "Modality", "Outcome", "Outpatients", "Patient Care", "Patient Preferences", "Patients", "Persons", "Positioning Attribute", "Process", "Provider", "Psychologist", "Psychotherapy", "Publishing", "Quality of Care", "Recording of previous events", "Research", "Research Personnel", "Research Priority", "Safety", "Sampling", "Scientist", "Services", "Site", "Suicide prevention", "Symptoms", "System", "Telemental", "Telephone", "Testing", "Time", "Training", "Travel", "Veterans", "Videoconferencing", "Work", "authority", "base", "caregiving", "comparative effectiveness", "connected care", "coronavirus disease", "cost", "design", "effectiveness implementation study", "effectiveness implementation trial", "effectiveness trial", "evidence base", "experience", "health care delivery", "hospitalization rates", "implementation strategy", "improved", "infection risk", "innovation", "pandemic disease", "preference", "prevent", "primary care services", "social stigma", "telehealth" ], "approved": true } }, { "type": "Grant", "id": "10695", "attributes": { "award_id": "1I21RX004092-01A1", "title": "Developing an Integrative, Recovery-Based, Post-Acute COVID-19 Syndrome (PACS) Psychotherapeutic Intervention", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-10-01", "end_date": "2024-09-30", "award_amount": null, "principal_investigator": { "id": 26752, "first_name": "Marianne", "last_name": "Goodman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1533, "ror": "", "name": "JAMES J PETERS VA MEDICAL CENTER", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "At present, 34.6 million people in the United States, and 273,232 Veterans tested or treated in Veteran Affairs facilities contracted COVID-19. While the exact prevalence of Post-Acute COVID-19 Syndrome (PACS) among Veterans is unknown, estimates of psychiatric/neurological PACS using a large global sample of COVID-19 patients (N=236,379) suggest a prevalence of approximately 11,390,400 Americans, and 90,311 Veterans in VA care, with rates likely to increase over time. Moreover, large scale studies suggest up to 35% of individuals experience functional impairment 8 months after COVID-19, and high prevalence of post-infection mental illness including anxiety disorders, depression, and post-traumatic stress disorder. Using longitudinal data from our academic affiliate, Icahn School of Medicine at Mount Sinai’s COVID registry (n≈1200), and local James J. Peters VA’s Clinical PACS program, coupled with our expertise in recovery-based psychotherapy, we are uniquely poised to develop an innovative treatment for Veterans struggling with PACS. Our intervention aims to improve psychological adjustment to PACS symptoms, promote resiliency, and facilitate coping, all of which can impact functional status and quality of life. The PACS-Coping and Recovery (PACS-CR) intervention we aim to develop focuses on psychological adjustment and coping, and augments medical, rehabilitative and neurological treatment for this population. Our approach is based on the CHIME model of personal recovery which includes five overarching processes: 1) Connectedness; 2) Hope and optimism about the future; 3) Identity; 4) Meaning in life; and 5) Empowerment. We will target the CHIME processes using established psychotherapeutic techniques such as skills training, acceptance-based and identity-based principles. Based on adaptations from existing recovery-based and COVID-19 distress group interventions that our team has developed and piloted, we are proposing a treatment framework that consists of a core of twelve 90-minutes sessions (1x/week x 12 weeks) with additional weekly sessions on specialized topics that are optional. We are proposing a treatment development NIH Stage 1A study to develop a Post-Acute COVID-19 Syndrome psychotherapeutic intervention, “PACS Coping and Recovery” (PACS-CR) through an iterative development process while collecting pilot data to assess its acceptability and feasibility. Our treatment development SPiRE will focus on 1) determining the treatment needs of Veterans with PACS, 2) developing the treatment using pilot qualitative data and aided by stakeholder feedback, 3) refining the intervention by three iterative pilots of our groups, testing both in person and telehealth versions. Pre and post measures will be utilized to track functional improvement and the degree to which this recovery-focused intervention has enabled the veterans to engage in meaningful life changes.", "keywords": [ "Activities of Daily Living", "Acute", "Address", "American", "Anxiety", "Anxiety Disorders", "Arthralgia", "COVID-19", "COVID-19 patient", "Cardiovascular system", "Caring", "Chronic", "Climacteric", "Clinical", "Consultations", "Contracts", "Coping Skills", "Coupled", "Data", "Development", "Disease", "Distress", "Education", "Employment", "Epidemiology", "Fatigue", "Feedback", "Fostering", "Future", "Goals", "Headache", "Health", "High Prevalence", "Impairment", "Individual", "Infection", "Intervention", "Interview", "Knowledge", "Leadership", "Life", "Life Style", "Loneliness", "Long COVID", "Longitudinal Studies", "Measures", "Medical", "Memory impairment", "Mental Depression", "Mental Health", "Mental disorders", "Modeling", "Needs Assessment", "Neurologic", "Neurologic Symptoms", "Nutritionist", "Pain", "Pain Disorder", "Participant", "Patients", "Persons", "Phase", "Population", "Post-Traumatic Stress Disorders", "Prevalence", "Process", "Protocols documentation", "Provider", "Psychological adjustment", "Psychotherapy", "Quality of life", "Recovery", "Registries", "Rehabilitation therapy", "Sampling", "Services", "Sleep Disorders", "Sleeplessness", "Specialist", "Symptoms", "Techniques", "Testing", "Time", "United States", "United States Department of Veterans Affairs", "United States National Institutes of Health", "Veterans", "acceptability and feasibility", "arm", "base", "cohort", "common symptom", "coping", "coronavirus disease", "design", "disorder later incidence prevention", "empowerment", "experience", "fitness", "flexibility", "follow-up", "functional disability", "functional improvement", "functional status", "group intervention", "health assessment", "improved", "innovation", "interdisciplinary approach", "medical schools", "neurological rehabilitation", "novel", "optimism", "physical conditioning", "post SARS-CoV-2 infection", "programs", "psychosocial", "pulmonary symptom", "rehabilitation strategy", "resilience", "satisfaction", "skills", "skills training", "sleep health", "symptomatology", "telehealth", "therapy development" ], "approved": true } }, { "type": "Grant", "id": "10696", "attributes": { "award_id": "1I01RX003656-01A2", "title": "INDIVIDUAL PLACEMENT AND SUPPORT FOR VETERANS WITH OPIOID USE DISORDER: A MIXED METHODS STUDY", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-10-01", "end_date": "2026-09-30", "award_amount": null, "principal_investigator": { "id": 25523, "first_name": "LORI L.", "last_name": "DAVIS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 24118, "first_name": "Mercy N", "last_name": "Mumba", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1699, "ror": "", "name": "TUSCALOOSA VETERANS AFFAIRS MEDICAL CTR", "address": "", "city": "", "state": "AL", "zip": "", "country": "United States", "approved": true } ] } ], "awardee_organization": { "id": 1699, "ror": "", "name": "TUSCALOOSA VETERANS AFFAIRS MEDICAL CTR", "address": "", "city": "", "state": "AL", "zip": "", "country": "United States", "approved": true }, "abstract": "Background: Living with an opioid use disorder (OUD) can make finding and sustaining employment a significant challenge and is only getting worse in the COVID-19 environment. With states reporting unemployment rates as high as 15-20%, the negative effects of unemployment on OUD treatment outcomes are expected to deteriorate. The COVID-19 pandemic has further resulted in treatment disruptions that are exacerbating poor outcomes, because of unemployment, social isolation, interrupted access to medication for OUD treatment (MOUD), and interference of daily routines that provide the necessary structure for many people with OUD. Our group has conducted research that shows Individual Placement and Support (IPS) is efficacious in yielding more weeks worked and higher steady employment rates for Veterans with posttraumatic stress disorder and Veterans diagnosed with a broad range of mental conditions (including substance use) being treated in a primary care setting; however, little is known about its efficacy in Veterans with OUD. Only one small study in civilians (n=45) with OUD has been conducted, in which 50% of the participants assigned to IPS gained employment compared to 5% of waitlist control at 6 months follow-up (p<0.001). A systematic review of effectiveness of IPS with conditions other than serious psychiatric mental illness revealed major limitations in many studies, including small sample sizes, major modifications to IPS model, weak control, and short follow-up periods. A larger randomized controlled trial of IPS for Veterans recovering from OUD with longer follow-up period, strong treatment control, and strict adherence to IPS fidelity, such as the one we propose, is warranted. Methods: This is a prospective, multi-site, randomized controlled trial to determine the efficacy of IPS compared to non-IPS Treatment-as-Usual Vocational Rehabilitation (TAU-VR) in a sample of 120 Veterans recovering from OUD (Aim 1). Investigators hypothesize that Veterans with OUD randomized to IPS will work significantly more weeks in a competitive job over 15 months compared to the non-IPS TAU-VR group. Additionally, compared to non-IPS TAU-VR, IPS recipients will earn significantly more income from competitive jobs and be significantly more likely to achieve steady employment. The investigators will also evaluate self-report measures of resilience, quality of life, perceived stress, community engagement, depression, anxiety, abstinence self-efficacy and suicide risk. As Aim 2, using a Community Based Participatory Research (CBRP) approach, the investigators will identify the contextual barriers to and facilitators of implementing vocational services for Veterans in both the IPS and non-IPS TAU-VR study arms, including evaluation of employment challenges, optimal occupational functioning, and OUD treatment adherence, with specific emphasis on the impact of COVID-19 and social distancing. To address Aim 2, the investigators will conduct semi-structured interviews with Veterans with OUD randomized to IPS or non-IPS TAU-VR. These interviews will be supplemented by qualitative findings from an ongoing Rehabilitation R&D pilot study that includes qualitative interviews on the same topic with IPS specialists, providers, unemployed veterans with OUD, and potential employers. Working with a CBPR Steering Committee, findings will be aggregated to reach consensus on best practices for IPS implementation in this new population. In an Exploratory Aim 3, the impact of IPS will be compared to non-IPS TAU-VR on participants’ adherence to MOUD and rates of OUD relapse. Significance: This study seeks to find the best intervention for successful recovery and functional reintegration for Veterans recovering from OUD. This study is especially timely given the societal impact of the COVID-19 pandemic on employment and mental health problems of the general population, and Veterans specifically. Additionally, with the new VHA plan to expand supported employment services to Veterans with substance use disorders in the coming years, our study is timely and can significantly contribute to the evidence required to successfully implement and sustain supported employment services in this new priority population.", "keywords": [ "Abstinence", "Address", "Adherence", "Anxiety", "Area", "Back", "COVID-19", "COVID-19 impact", "COVID-19 pandemic", "COVID-19 pandemic effects", "Communities", "Consensus", "Control Groups", "Data", "Diagnosis", "Economic Burden", "Economics", "Effectiveness", "Employment", "Environment", "Evaluation", "Feeling hopeless", "Foundations", "General Population", "Goals", "Homelessness", "Income", "Individual", "Interruption", "Intervention", "Interview", "Link", "Measures", "Mental Depression", "Mental Health", "Mental disorders", "Methods", "Modeling", "Modification", "Occupational", "Occupations", "Outcome", "Participant", "Patient Self-Report", "Persons", "Pharmaceutical Preparations", "Pilot Projects", "Population", "Post-Traumatic Stress Disorders", "Poverty", "Prevention", "Process", "Provider", "Psyche structure", "Public Health", "Publishing", "Quality of life", "Randomized", "Randomized Controlled Trials", "Recovery", "Rehabilitation therapy", "Relapse", "Reporting", "Research", "Research Personnel", "Research Support", "Resources", "Sample Size", "Sampling", "Self Efficacy", "Services", "Site", "Social Distance", "Social isolation", "Socialization", "Specialist", "Structure", "Substance Use Disorder", "Supported Employment", "Symptoms", "Time", "Treatment outcome", "Unemployment", "Veterans", "Vocational rehabilitation", "Waiting Lists", "Work", "arm", "community based participatory research", "community engagement", "design", "disorder later incidence prevention", "effectiveness evaluation", "efficacy evaluation", "efficacy testing", "evidence base", "experience", "follow-up", "functional independence", "implementation evaluation", "implementation facilitators", "improved", "interest", "methadone treatment", "opioid epidemic", "opioid use disorder", "patient population", "perceived stress", "prevent", "primary care setting", "prospective", "rehabilitation service", "research and development", "resilience", "rural area", "substance use", "success", "suicidal risk", "systematic review", "treatment adherence", "treatment as usual" ], "approved": true } }, { "type": "Grant", "id": "10697", "attributes": { "award_id": "1I01RX003639-01A2", "title": "Home-Based Exercise Tele-Rehabilitation in High-Risk Veterans: Impact of COVID-19 Exposure and Socioeconomic Factors", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-10-01", "end_date": "2026-09-30", "award_amount": null, "principal_investigator": { "id": 26753, "first_name": "KRISANN K", "last_name": "OURSLER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26754, "first_name": "ALICE S.", "last_name": "RYAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1532, "ror": "https://ror.org/036a0e562", "name": "Baltimore VA Medical Center", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": null, "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 1384, "pages": 1392, "count": 13920 } } }